Pharmacodynamics of non-break weekly paclitaxel (Taxol) and pharmacokinetics of Cremophor-EL vehicle: Results of a dose-escalation study

Anti-Cancer Drugs

Volumn 13, Issue 5, 2002, Pages 481-489

  Briasoulis, Evangelos ^a   Karavasilis, Vasilis ^a   Tzamakou, Eleftheria ^a   Haidou, Constantina ^a   Piperidou, Christina ^a   Pavlidis, Nicholas ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Cremophor EL; Paclitaxel; Pharmacokinetics; Taxol; Weekly administration

Indexed keywords

CREMOPHOR; PACLITAXEL; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; DRUG VEHICLE; GLYCEROL; SURFACTANT;

ALOPECIA; AREA UNDER THE CURVE; ARTICLE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG TOLERANCE; FEBRILE NEUTROPENIA; GRANULOCYTOPENIA; HUMAN; MYALGIA; NEUROTOXICITY; PRIORITY JOURNAL; SOLID TUMOR; ADULT; AGED; CHEMICALLY INDUCED DISORDER; FEMALE; MALE; MAXIMUM TOLERATED DOSE; METABOLISM; MIDDLE AGED; NEOPLASM; NEUTROPENIA; PATHOLOGY; VEHICLES;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLYCEROL; HUMAN; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGE; NEOPLASMS; NEUTROPENIA; PACLITAXEL; SURFACE-ACTIVE AGENTS; VEHICLES; HUMANS; MIDDLE AGED;

EID: 0035987099     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200206000-00006     Document Type: Article

References (33)

1. Paclitaxel
2. One-hour paclitaxel via weekly infusion: Dose-density with enhanced therapeutic index
3. The microtubule-affecting drug paclitaxel has antiangiogenic activity
4. Paclitaxel (Taxol): An inhibitor of angiogenesis in a highly vascularized transgenic breast cancer
5. Cremophor-EL pharmacokinetics in a phase I study of paclitaxel (Taxol) and carboplatin in non-small cell lung cancer patients
6. Cremophor-EL: The drawbacks and advantages of vehicle selection for drug formulation
7. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations
8. Determination of polyoxyethylene-glycerol triricinoleate 35 (Cremophor-EL in plasma by pre-column derivatization and reversed-phase high-performance liquid chromatography
9. Reversal of the multidrug resistance phenotype with Cremophor-EL a common vehicle for water-insoluble vitamins and drugs
10. Measurement of Cremophor-EL following taxol: Plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype
11. Phase I study of weekly outpatient paclitaxel and concurrent cranial irradiation in adults with astrocytomas
12. Haematopoietic radioprotection by Cremophor-EL: A polyethoxylated castor oil
13. Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma
14. Weekly 1-hour infusion of paclitaxel. Clinical feasibility and efficacy in patients with hormone-refractory prostate carcinoma
15. Weekly paclitaxel (P) followed by FAC in the neo-adjuvant setting provides improved pathologic complete remission (PCR) rates compared to standard paclitaxel followed by FAC therapy - Preliminary results of an ongoing prospective randomized trial
16. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer
17. Phase I trial of weekly paclitaxel in advanced lung cancer
18. A phase I-II study of bi-weekly paclitaxel as first-line treatment in metastatic breast cancer
19. Cytotoxic studies of paclitaxel (Taxol) in human tumour cell lines
20. Effects of paclitaxel with or without Cremophor-EL on cellular clonogenic survival and apoptosis
21. Cell line and schedule-dependent cytotoxicity of paclitaxel (Taxol): Role of the solvent Cremophor-EL/ethanol
22. Effect of the paclitaxel vehicle Cremophor-EL on the pharmacokinetics of doxorubicin and doxorubicinol in mice
23. Disposition of Cremophor-EL in humans limits the potential for modulation of the multidrug resistane phenotype in vivo
24. Interrelationships of paclitaxel disposition infusion duration and Cremophor-EL kinetics in cancer patients
25. Paclitaxel-induced cytotoxicity - The effects of Cremophor-EL (castor oil) on two human breast cancer cell lines with acquired multidrug resistant phenotype and induced expression of the permeability glycoprotein
26. Biotransformation of taxoids by human cytochromes P450: Structure-activity relationship
27. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux
28. Phase I trial of paclitaxel in children with refractory solid tumors: A pediatric oncology group study
29. A Phase II study of paclitaxel in patients with recurrent malignant glioma using different doses depending upon the concomitant use of anticonvulsants: A North American Brain Tumor Consortium report
30. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer
31. Schedule- and dose-intensified paclitaxel as weekly 1-hour infusion in pretreated solid tumors: Results of a phase I/II trial
32. Phase I study with a weekly 1 h infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancer
33. Phase I study of a weekly 1 h infusion of paclitaxel in patients with unresectable hepatocellular carcinoma